News Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Staff September 11, 2023 Iframe sync Post navigation Previous: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research ConferenceNext: Major shareholder announcement – BlackRock, Inc. More Stories Healthcare News Pharmaceutical MDaudit Recognized as One of Modern Healthcare’s Best in Business Staff January 12, 2026 Healthcare News Pharmaceutical MDaudit Recognized as One of Modern Healthcare’s Best in Business Staff January 12, 2026 Healthcare Hospitals News Pharmaceutical US Med-Equip Recognized as One of Modern Healthcare’s Best in Business Staff January 12, 2026
